- Home
- PTHS
as 07-15-2025 4:00pm EST
Stocks
Pelthos Therapeutics Inc is a clinical-stage biotechnology company developing and commercializing novel, non-opioid, non-addictive therapeutics to alleviate pain. The initial clinical focus is to selectively target the sodium ion channel known as NaV1.7 for the treatment of various types of chronic, visceral pain, acute and chronic eye pain, and post-surgical nerve blocks. Its pipeline includes CC8464 for ISFN and EM and CT2000 for Acute and CHronic Eye Pain-Dry Eye Disease.
| Founded: | 2002 | Country: | United States |
| Employees: | N/A | City: | NORTH BRUNSWICK |
| Market Cap: | 17.1M | IPO Year: | N/A |
| Target Price: | N/A | AVG Volume (30 days): | 167.6K |
| Analyst Decision: | N/A | Number of Analysts: | N/A |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -12.40 | EPS Growth: | N/A |
| 52 Week Low/High: | $4.50 - $54.29 | Next Earning Date: | 08-12-2025 |
| Revenue: | N/A | Revenue Growth: | N/A |
| Revenue Growth (this year): | N/A | Revenue Growth (next year): | N/A |
Latest PELTHOS THERAPEUTICS INC News
PTHS Breaking Stock News: Dive into PTHS Ticker-Specific Updates for Smart Investing
MT Newswires
5 days ago
Sector Update: Health Care Stocks Rise Late Afternoon
MT Newswires
5 days ago
Sector Update: Health Care
MT Newswires
6 days ago
Top Midday Gainers
MT Newswires
6 days ago
Ligand Pharmaceuticals Partner Pelthos Launches Molluscum Contagiosum Treatment Zelsuvmi
GlobeNewswire
6 days ago
Pelthos Therapeutics Launches ZELSUVMI™ (berdazimer) Topical Gel 10.3%, the First and Only FDA-Approved At-Home Treatment for Molluscum Contagiosum
Compare PTHS vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "PTHS PELTHOS THERAPEUTICS INC - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.